The first case report of Enterococcus gallinarum meningitis in neonate

Li, Xiaoquan; Fan, Shujuan; Lin, Xi Victoria; Liu, Li; Zheng, Jie; Zhou, Xihui; Heep, Axel

doi:10.1097/md.0000000000009875

Cited by 8 publications

(5 citation statements)

References 6 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…faecium accounts for approximately 90% of enterococcal meningitis cases. CNS infections caused by E. gallinarum are rare but have been reported more often in recent years 11–14 . Consistent with other reports, E. faecalis and E. faecium were common, whereas E. gallinarum was isolated in only three patients in our study.…”

Section: Discussionsupporting

confidence: 92%

Experience with enterococcal meningitis/ventriculitis in children

Çay

Alabaz

Gündeşlioglu

et al. 2023

Pediatrics International

View full text Add to dashboard Cite

BackgroundEnterococcal infections are increasingly common in hospitalized patients. Enterococcal meningitis/ventriculitis (EMV) is an extremely rare condition of enterococcal infections, occurring particularly in children. This study investigated the clinical and microbiological characteristics, predisposing factors, and prognosis in pediatric patients with EMV.MethodsPediatric patients (<18 years) diagnosed with EMV were retrospectively evaluated over 10 years.ResultsThe study included a total of 25 isolates from 24 patients, median age 23 months (range: 1–136 months). The most common symptoms included vomiting, fever, and headache, with hydrocephalus shunt and preterm birth being the two most common conditions. Commonly associated infections, with central nervous system (CNS) devices as a predisposing factor, were due to external ventricular drainage and ventriculoperitoneal shunts. Two patients with spontaneous meningitis were preterm infant. Of the isolates, 44% were Enterococcus faecalis, 44% E. faecium, and 12% E. gallinarum. Five (20%) isolates were vancomycin resistant. Twelve patients were resistant to anti‐enterococcal antibiotics, including ampicillin, ciprofloxacin, imipenem, teicoplanin, gentamicin, and linezolid (40%, 20%, 8%, 8%, 4%, and 4%, respectively). Enterococcus faecium was more resistant to ampicillin, ciprofloxacin, teicoplanin, and vancomycin than E. faecalis. The median treatment duration was 17 days (interquartile range: 14–26 days).The mortality rate was 8.3% (2/24; both associated with vancomycin resistance).ConclusionsNeurosurgical conditions are the most common predisposing factors for EMV. Preterm birth is an important predisposing factor in children. Because EMV is nonspecific in clinical findings, it should be considered when there is an underlying CNS disorder and empirical treatment should begin in this direction.

show abstract

Section: Discussionsupporting

confidence: 92%

Experience with enterococcal meningitis/ventriculitis in children

Çay

Alabaz

Gündeşlioglu

et al. 2023

Pediatrics International

View full text Add to dashboard Cite

show abstract

“…Stenotrophomonas maltophilia was never reported in rabbits or hares, being an aerobic, non-fermentative, Gram-negative bacterium, uncommon and difficult to treat in humans [ 45 ]. Enterococcus gallinarum was also never reported in hares or rabbits, also being of zoonotic importance [ 46 , 47 ]. The Vibrio vulnificus is a multi-host opportunistic bacteria [ 48 ] never reported in leporids.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Commercial Myxomatosis Vaccines against Recombinant Myxoma Virus (ha-MYXV) in Iberian Hare and Wild Rabbit

et al. 2022

View full text Add to dashboard Cite

The recent emergence of a new myxoma virus capable of causing disease in the Iberian hare (Lepus granatensis) has resulted in numerous outbreaks with high mortality leading to the reduction, or even the disappearance, of many local populations of this wild species in the Iberian Peninsula. Currently, the available vaccines that prevent myxomatosis in domestic rabbits caused by classic strains of myxoma virus have not been assessed for use in Iberian hares. The main objective of this study was to evaluate the efficacy of commercial rabbit vaccines in Iberian hares and wild rabbits against the natural recombinant myxoma virus (ha-MYXV), bearing in mind its application in specific scenarios where capture is possible, such as genetic reserves. The study used a limited number of animals (pilot study), 15 Iberian hares and 10 wild rabbits. Hares were vaccinated with Mixohipra-FSA vaccine (Hipra) and Mixohipra-H vaccine (Hipra) using two different doses, and rabbits were vaccinated with the Mixohipra-H vaccine or the Nobivac Myxo-RHD PLUS (MSD Animal Health) using the recommended doses for domestic rabbits. After the vaccination trials, the animals were challenged with a wild type strain of ha-MYXV. The results showed that no protection to ha-MYXV challenge was afforded when a commercial dose of Mixohipra-FSA or Mixohipra-H vaccine was used in hares. However, the application of a higher dose of Mixohipra-FSA vaccine may induce protection and could possibly be used to counteract the accelerated decrease of wild hare populations due to ha-MYXV emergence. The two commercial vaccines (Mixohipra-H and Nobivac Myxo-RHD PLUS) tested in wild rabbits were fully protective against ha-MYXV infection. This knowledge gives more insights into ha-MYXV management in hares and rabbits and emphasises the importance of developing a vaccine capable of protecting wild populations of Iberian hare and wild rabbit towards MYXV and ha-MYXV strains.

show abstract

“…Expõe-se ainda, que outros fatores de risco presentes são: crianças que passaram por procedimentos invasivos no sistema nervoso central, como a colocação de válvula ventrículo-peritoneal, malformação do SNC, neonatos do sexo masculino, em casos de gemelaridade, asfixia, bebês que necessitaram de manobras de ressuscitação, doenças metabólicas, infecções do trato urinário gestacional e febre materna (KREBS, TARICCO, 2004;HAUSSEN, et.al., 2005;LI, et. al., 2018).…”

Section: Resultsunclassified